NCM · Biotechnology
CRVO (CRVO) Stock
$2.56
-3.76%
NCM: CRVO
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
GlobeNewswire · Jul 14, 2026
CervoMed Completes Enrollment in Phase 2a Study of Neflamapimod in Frontotemporal Dementia
MT Newswires · Jul 9, 2026
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
GlobeNewswire · Jul 9, 2026
CervoMed Files for Resale of Common Shares
MT Newswires · Jul 6, 2026
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
GlobeNewswire · Jul 6, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held29.55%
Institutions Held19.11%
Institutions Float Held27.13%
Peer Comparison
About CRVO
CRVO is led by CEO John J. Alam, employs 15 people, headquartered in US, publicly traded since 2008.
CRVO stock trades at $2.56 with a market capitalization of $23.70M. The stock is valued at a price-to-earnings (P/E) ratio of -1.09, price-to-book of 1.67, price-to-sales of 87.83. Over the past 52 weeks the stock has ranged between $2.13 and $13.13, and currently trades 80.5% below its 52-week high.
On profitability, CRVO generates a return on equity (ROE) of -150.00%, return on capital employed of -155.56%, an operating margin of 0.00%, a net profit margin of -93.12%.